Flex Pharma (FLKS) Tops Q2 EPS by 7c

Flex Pharma (NASDAQ: FLKS) reported Q2 EPS of ($0.51), $0.07 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $331 thousand versus the consensus estimate of $520 thousand.

For earnings history and earnings-related data on Flex Pharma (FLKS) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Goldman Sachs Starts Brunello Cucinelli SpA (BC:IM) (BCUCF) at Neutral
• Evercore ISI Upgrades Texas Roadhouse (TXRH) to Outperform